How to Help Your Patients Save Money on Fintepla: A Provider's Guide to Savings Programs

Fintepla (fenfluramine) is a specialty medication for rare epilepsy syndromes, and like most specialty drugs, it carries a high list price. However, the manufacturer UCB has established comprehensive financial assistance programs that make Fintepla affordable for the vast majority of patients. As a prescribing provider, understanding these programs — and proactively connecting patients with them — can prevent treatment interruptions and improve outcomes.

Overview: What Fintepla Costs Patients in 2026

Commercial insurance + ONWARD copay assistance: $0–$25/month out-of-pocket (99% of eligible patients)

Medicaid: $4.95–$9.85/month average; $0 for exempt populations (children, terminally ill, institutionalized)

Medicare: Varies by plan, coverage phase, and Extra Help eligibility

Uninsured/underinsured: Patient assistance program through UCB ONWARD — contact for eligibility

Program 1: UCB ONWARD Copay Assistance Program

The most impactful savings program for your commercially insured patients is the UCB ONWARD Copay Assistance Program. Here are the key details your office needs to know:

Patient benefit: Pay as little as $0/month; guaranteed maximum of $25/month for Fintepla. Also covers echocardiogram costs required by the REMS program.

Eligibility: Must have commercial (employer or self-insured) health insurance; valid prescription from REMS-certified prescriber; resident of US or Puerto Rico

Not eligible: Medicaid, Medicare, or other government insurance beneficiaries. State restrictions may apply.

How to enroll: Patients call 1-833-463-7547 or providers can initiate enrollment through the ONWARD team

Provider tip: Build ONWARD referral into your Fintepla prescribing workflow — at the same visit you write the prescription, give patients the ONWARD contact information and encourage them to call immediately.

Program 2: Medicaid Coverage

Fintepla is covered by Medicaid in most states, with average patient copayments of $4.95 to $9.85 per month. Several Medicaid populations are fully exempt from cost-sharing:

Children (varying by state)

Terminally ill patients

Institutionalized individuals

Note that Medicaid patients are not eligible for the ONWARD Copay Assistance Program. For Medicaid patients, contact Zogenix Central (1-888-964-3649) for guidance on state-specific coverage and costs.

Program 3: Patient Assistance for Uninsured and Underinsured Patients

For patients who are uninsured or for whom insurance does not cover Fintepla, UCB provides a patient assistance program through ONWARD (1-833-463-7547). Based on financial need, qualifying patients may receive Fintepla at reduced cost or at no charge. Criteria and documentation requirements apply.

Also recommend that patients explore:

State Pharmaceutical Assistance Programs (SPAPs) — especially relevant for elderly or disabled patients

Medicare Extra Help / Low-Income Subsidy — for Medicare Part D patients with limited income and resources

Program 4: Epilepsy and Rare Disease Foundation Grants

Several nonprofit organizations offer financial assistance that can help offset remaining medication or echocardiogram costs:

Epilepsy Foundation: Medication Access Program and community grants

Dravet Syndrome Foundation: Family resources and referrals to financial assistance

LGS Foundation: Medication access assistance information for LGS patients

Patient Advocate Foundation: Co-pay relief and insurance navigation support

Insurance Denial and Appeals Support

When a patient's initial PA is denied, the financial impact can be significant. Your office can help by:

Filing a thorough appeal with seizure logs, genetic/EEG documentation, and full AED failure history

Requesting peer-to-peer review with the insurance company's medical director

Escalating to an external independent review organization (IRO) if internal appeal fails

Using UCB's ONWARD program as an appeals support resource (1-833-463-7547)

Using medfinder to Help Patients Access Specialty Pharmacies

Once insurance is approved, patients still need to locate a REMS-certified specialty pharmacy that accepts their plan. medfinder for providers contacts pharmacies on patients' behalf to identify which REMS-certified locations can fill Fintepla. This reduces administrative burden on your staff and ensures patients don't face access delays after insurance approval. For a patient-facing resource on Fintepla costs, direct patients to: How to Save Money on Fintepla in 2026.